MX2009011226A - Inhibidores especificos pdgfrbeta. - Google Patents
Inhibidores especificos pdgfrbeta.Info
- Publication number
- MX2009011226A MX2009011226A MX2009011226A MX2009011226A MX2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A MX 2009011226 A MX2009011226 A MX 2009011226A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- pdgfrbeta
- specific inhibitors
- pdgfr
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fuel Cell (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invenci?n se refiere a nuevos antagonistas espec?ficos de PDGFR?. Los antagonistas incluyen anticuerpos, los cuales pueden ser biespec?ficos. Los anticuerpos se usan para reducir o inhibir el crecimiento de tumor o para tratar una enfermedad angiog?nica. La invenci?n tambi?n incluye combinaciones de antagonistas espec?ficos de PDGFR? con antagonistas VEGFR para tales tratamientos. Los antagonistas pueden adem?s ser administrados en combinaci?n con otros f?rmacos anti-angiog?nicos o anti-neopl?sticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92397907P | 2007-04-17 | 2007-04-17 | |
PCT/US2008/005137 WO2008130704A2 (en) | 2007-04-17 | 2008-04-17 | PDGFRβ-SPECIFIC INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009011226A true MX2009011226A (es) | 2010-04-01 |
Family
ID=39837443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011226A MX2009011226A (es) | 2007-04-17 | 2008-04-17 | Inhibidores especificos pdgfrbeta. |
Country Status (14)
Country | Link |
---|---|
US (3) | US7740850B2 (es) |
EP (1) | EP2139921A2 (es) |
JP (1) | JP5209702B2 (es) |
KR (1) | KR101136262B1 (es) |
CN (1) | CN101707882A (es) |
AU (1) | AU2008242444B2 (es) |
BR (1) | BRPI0810374A2 (es) |
CA (1) | CA2682390A1 (es) |
EA (1) | EA019595B1 (es) |
IL (1) | IL200779A0 (es) |
MX (1) | MX2009011226A (es) |
NZ (1) | NZ579734A (es) |
UA (1) | UA99608C2 (es) |
WO (1) | WO2008130704A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2604280A3 (en) | 2008-03-27 | 2013-10-16 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
US20120231537A1 (en) * | 2008-04-30 | 2012-09-13 | Gradalis, Inc. | Highly Pure Plasmid DNA Preparations |
JP5693449B2 (ja) * | 2008-04-30 | 2015-04-01 | グラダリス インク.Gradalis, Inc. | 高純度のプラスミドdna調製物及びその調製方法 |
US20110305672A1 (en) | 2008-07-25 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME |
EP2379718B2 (en) | 2008-12-16 | 2020-12-30 | Novartis AG | Yeast display systems |
TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
WO2011036305A2 (en) * | 2009-09-28 | 2011-03-31 | Medizinische Universität Wien | New use of pdgfrbeta inhibitors |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
EP3798236B1 (en) | 2011-03-15 | 2022-08-10 | X-Body, Inc. | Antibody screening methods |
CN102250249A (zh) * | 2011-06-18 | 2011-11-23 | 常州亚当生物技术有限公司 | 一种抗VEGF/PDGFRbeta双特异性抗体及其应用 |
CN103857700A (zh) | 2011-08-26 | 2014-06-11 | 梅里麦克制药股份有限公司 | 串联fc双特异性抗体 |
EP3712173B1 (en) | 2011-12-05 | 2023-07-12 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗-大-內皮素-1(big-et-1)抗體及其用途 |
JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
EP3041513B1 (en) | 2013-09-08 | 2020-08-05 | Kodiak Sciences Inc. | Factor viii zwitterionic polymer conjugates |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
KR102127408B1 (ko) * | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3207128B1 (en) | 2014-10-17 | 2022-07-27 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
JP2018517660A (ja) | 2015-03-20 | 2018-07-05 | ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン | 周皮細胞長鎖非コーディングrna |
WO2017106609A2 (en) * | 2015-12-16 | 2017-06-22 | Kadmon Corporation, Llc. | Pdgfr beta antibody |
MX2018005384A (es) | 2015-12-16 | 2018-08-16 | Regeneron Pharma | Composiciones y metodos para fabricar microparticulas de proteina. |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
AU2017348475B2 (en) * | 2016-10-30 | 2024-02-08 | Shanghai Henlius Biotech, Inc. | Anti-PD-L1 antibodies and variants |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018169785A2 (en) * | 2017-03-13 | 2018-09-20 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Therapeutic antibodies to marburg virus |
CN109021104B (zh) * | 2017-06-12 | 2022-08-12 | 上海睿智化学研究有限公司 | 一种抗人血小板衍生生长因子β受体的抗体及其应用 |
US11795221B2 (en) | 2018-02-28 | 2023-10-24 | WuXi Biologics Ireland Limited | Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof |
DE102018204828A1 (de) | 2018-03-29 | 2019-10-02 | Ford Global Technologies, Llc | Verhinderung von Glatteis durch Abwasser von Kraftfahrzeugen |
US11773155B2 (en) | 2018-08-09 | 2023-10-03 | Beijing Wisdomab Biotechnology Co., Ltd | Bispecific antibody against rabies virus, and application thereof |
WO2020071881A1 (ko) * | 2018-10-05 | 2020-04-09 | 서울대학교산학협력단 | Pdgf 수용체에 대한 항체 및 이의 용도 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
KR20220140551A (ko) * | 2020-02-07 | 2022-10-18 | 바이오리온 테크놀러지스 비.브이. | 혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH06507543A (ja) | 1991-01-31 | 1994-09-01 | コア セラピューティクス,インコーポレイティド | ヒト血小板由来成長因子レセプターポリペプチドの細胞外領域ドメイン |
US20020009443A1 (en) * | 1991-12-02 | 2002-01-24 | Vanitha Ramakrishman | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5817310A (en) * | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
US5620687A (en) | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
US5976534A (en) | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US6259971B1 (en) * | 1997-06-30 | 2001-07-10 | Compaq Computer Corporation | Portable fuel-cell-powered system with ultrasonic atomization of H2O by-product |
US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US7413823B2 (en) * | 2000-09-22 | 2008-08-19 | Siemens Aktiengesellschaft | Method for monitoring the discharge of media out of fuel cell, and a fuel cell system |
EP1313161A1 (en) * | 2001-11-15 | 2003-05-21 | Ballard Power Systems AG | Fuel cell system and method for operating the same |
US7582726B2 (en) * | 2003-11-10 | 2009-09-01 | Ghc Research Development Corporation | VEGF receptor antagonists |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
-
2008
- 2008-04-17 WO PCT/US2008/005137 patent/WO2008130704A2/en active Application Filing
- 2008-04-17 CN CN200880012257A patent/CN101707882A/zh active Pending
- 2008-04-17 EP EP08743156A patent/EP2139921A2/en not_active Withdrawn
- 2008-04-17 NZ NZ579734A patent/NZ579734A/en not_active IP Right Cessation
- 2008-04-17 KR KR1020097021652A patent/KR101136262B1/ko not_active IP Right Cessation
- 2008-04-17 CA CA002682390A patent/CA2682390A1/en not_active Abandoned
- 2008-04-17 AU AU2008242444A patent/AU2008242444B2/en not_active Ceased
- 2008-04-17 UA UAA200910244A patent/UA99608C2/ru unknown
- 2008-04-17 MX MX2009011226A patent/MX2009011226A/es active IP Right Grant
- 2008-04-17 US US12/148,482 patent/US7740850B2/en not_active Expired - Fee Related
- 2008-04-17 JP JP2010504124A patent/JP5209702B2/ja not_active Expired - Fee Related
- 2008-04-17 EA EA200970953A patent/EA019595B1/ru not_active IP Right Cessation
- 2008-04-17 BR BRPI0810374-7A2A patent/BRPI0810374A2/pt not_active IP Right Cessation
- 2008-06-25 US US12/674,350 patent/US20110207005A1/en not_active Abandoned
-
2009
- 2009-09-07 IL IL200779A patent/IL200779A0/en unknown
-
2010
- 2010-04-21 US US12/764,121 patent/US20100221267A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008130704A3 (en) | 2008-12-24 |
EA019595B1 (ru) | 2014-04-30 |
US7740850B2 (en) | 2010-06-22 |
WO2008130704A2 (en) | 2008-10-30 |
AU2008242444A1 (en) | 2008-10-30 |
US20100221267A1 (en) | 2010-09-02 |
EP2139921A2 (en) | 2010-01-06 |
IL200779A0 (en) | 2010-05-17 |
CA2682390A1 (en) | 2008-10-30 |
AU2008242444B2 (en) | 2013-05-02 |
US20110207005A1 (en) | 2011-08-25 |
JP5209702B2 (ja) | 2013-06-12 |
BRPI0810374A2 (pt) | 2014-10-29 |
KR20090130382A (ko) | 2009-12-23 |
US20090053241A1 (en) | 2009-02-26 |
UA99608C2 (en) | 2012-09-10 |
CN101707882A (zh) | 2010-05-12 |
JP2010524466A (ja) | 2010-07-22 |
NZ579734A (en) | 2012-01-12 |
KR101136262B1 (ko) | 2012-07-05 |
EA200970953A1 (ru) | 2010-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009011226A (es) | Inhibidores especificos pdgfrbeta. | |
TW201129378A (en) | Materials and methods for treating or preventing HER-3 associated diseases | |
PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
PH12014502419A1 (en) | Specific binding proteins and uses thereof | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
EA201500393A1 (ru) | Ингибиторы тирозинкиназы брутона | |
EA201170155A1 (ru) | Специфические антагонисты рецептора fgf-r4 | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
EA201170940A1 (ru) | Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела | |
EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
MX2010009669A (es) | Terapia de combinacion con antagonistas de c-met y egfr. | |
NZ707477A (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
UA109658C2 (xx) | Антитіло проти cgrp | |
BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
MX2011013424A (es) | Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico. | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
AR102463A1 (es) | Inhibidor de cinasa aurora a | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |